The meningitis vaccine every college student should have is the MenB vaccine, which protects against serogroup B meningococcal disease — the strain responsible for 63 to 67 percent of meningococcal cases among college students aged 18 to 24. Most incoming freshmen have already received the MenACWY vaccine, which covers serogroups A, C, W, and Y, because 26 states mandate it for college entry. But the MenB vaccine is a different shot entirely, and fewer than 20 percent of teens have completed the recommended two-dose series. That gap leaves the majority of college students unprotected against the very strain most likely to circulate in their dorms, dining halls, and social circles.
This distinction matters more than most families realize. In 2023, a cluster of meningococcal B cases at a mid-Atlantic university sent several students to the ICU — students who had dutifully gotten their required MenACWY shot but had never been offered the MenB vaccine. Meningococcal disease carries a 10 to 15 percent fatality rate even with aggressive treatment, and one in five survivors suffers lasting consequences including brain damage, hearing loss, seizures, or limb amputation. For a site focused on brain health and dementia care, the neurological stakes of bacterial meningitis deserve particular attention: the inflammation and damage this infection inflicts on the brain and its membranes can produce cognitive deficits that persist for years. This article breaks down the specific vaccines available, the CDC-recommended schedule and why timing matters, state-by-state requirements, the coverage gaps that leave students vulnerable, and the newer pentavalent vaccines that may finally simplify the whole process.
Table of Contents
- Which Meningitis Vaccines Do College Students Actually Need?
- The CDC-Recommended Schedule and Why Timing Is Not Flexible
- State Requirements Create a Patchwork of Protection
- Pentavalent Vaccines May Solve the Two-Shot Problem
- The Neurological Stakes of Meningococcal Disease
- What Parents and Students Should Do Before Move-In Day
- Where Meningitis Vaccination Policy Is Heading
- Conclusion
- Frequently Asked Questions
Which Meningitis Vaccines Do College Students Actually Need?
There are two categories of meningococcal vaccine, and they are not interchangeable. The MenACWY vaccine — sold under brand names Menactra and Menveo — protects against four serogroups and is the one most colleges require. The CDC recommends a first dose at age 11 to 12 with a booster at age 16, and first-year students living in residence halls should have received at least one MenACWY dose within five years of entering college. This vaccine has strong uptake: 90.7 percent of 17-year-olds have received at least one dose, though only 60.8 percent have completed the recommended two-dose series. The MenB vaccine is the overlooked one. Brands include Trumenba, made by Pfizer, and Bexsero, made by GSK.
The CDC classifies MenB vaccination as a “shared clinical decision” for ages 16 to 18, which means a doctor should discuss it with the patient rather than automatically administering it. In practice, that softer recommendation means many pediatricians never bring it up, and many parents never know to ask. The result is a vaccination rate roughly one-third of MenACWY levels for even a single dose. Compare that to the fact that serogroup B drives the majority of campus outbreaks, and the mismatch between protection and risk becomes stark. A useful way to think about it: MenACWY is the vaccine colleges check for on your immunization form. MenB is the vaccine that would actually protect you during the outbreak most likely to hit your campus. Students need both for full coverage, yet the system is set up to ensure only one gets reliably administered.
The CDC-Recommended Schedule and Why Timing Is Not Flexible
The CDC recommends the MenB vaccine preferably at ages 16 to 18, given as two doses spaced six months apart. This timing is not arbitrary. MenB protection duration is limited to approximately one to two years, which means getting vaccinated at age 13 or 14 would leave a student unprotected by the time they move into a dorm at 18. The window is deliberately calibrated so that peak immunity coincides with the highest-risk period — those first semesters of college when students are sharing close quarters, cups, and irregular sleep schedules. However, if a student missed that 16-to-18 window, vaccination is still worthwhile through age 23. The protection will not last as long as many people assume — this is not a one-and-done lifetime shield like the MMR vaccine.
Families should understand that the MenB vaccine is more like a targeted defense for a specific high-risk period. A student vaccinated at 17 will have strong protection through their sophomore year but should discuss with their doctor whether additional considerations apply if they remain in congregate living situations beyond that. The MenACWY booster at age 16 is equally important and more straightforward. Many students received their first dose at 11 or 12 but never returned for the booster. Colleges that require MenACWY vaccination typically want documentation of a dose received at age 16 or later. Students who only have the childhood dose on record may find themselves scrambling to get a booster before move-in day — an avoidable hassle that a quick records check during junior year of high school can prevent.
State Requirements Create a Patchwork of Protection
Whether a college student is required to show proof of meningococcal vaccination depends heavily on geography. Twenty-six states mandate MenACWY vaccination for college entry, but only two states have specific MenB requirements. The Northeast leads with a 77.8 percent mandate rate, followed by the South at 64.7 percent, the Midwest at 41.7 percent, and the West at 23.1 percent. A student attending a university in Oregon faces a very different regulatory landscape than one heading to a school in Massachusetts. This patchwork creates a false sense of security. A student at a Western university with no mandate might assume meningococcal disease is not a concern in their region, when in reality the bacterium does not respect state lines.
Campus outbreaks have occurred in states with and without mandates. The mandates simply determine whether a university checks vaccination records — they do not determine whether the pathogen is present. Students and families in states without requirements should treat the CDC recommendations as their guide, not the absence of a state law. The two-state MenB mandate situation is particularly concerning given the epidemiology. If serogroup B accounts for nearly two-thirds of college-age meningococcal cases, a mandate structure that overwhelmingly focuses on MenACWY is addressing the smaller share of the risk. Public health advocates have pushed for broader MenB mandates, but the CDC’s “shared clinical decision” classification makes legislative action more complicated than it was for MenACWY, which carries a universal recommendation.
Pentavalent Vaccines May Solve the Two-Shot Problem
One reason MenB uptake has lagged is simple logistics: it was a separate vaccine requiring a separate conversation, separate appointments, and separate doses. Two newer pentavalent vaccines aim to collapse the complexity. Penbraya, made by Pfizer, has been recommended by the CDC’s Advisory Committee on Immunization Practices since October 25, 2023, for ages 16 to 23. Penmenvy, made by GSK, was licensed on February 14, 2025, and received an ACIP recommendation on April 16, 2025, for ages 10 to 25. Both combine MenACWY and MenB protection into a single shot, which could meaningfully improve coverage by eliminating the need for families to seek out and schedule a separate MenB vaccination. The tradeoff is that these are newer products with shorter track records.
Penbraya requires two doses, and the dosing schedule should be discussed with a healthcare provider to ensure it aligns with the student’s timeline before college. Penmenvy’s broader age range — starting at 10 rather than 16 — may offer more flexibility for pediatricians to work it into existing well-child visit schedules. For families weighing options, the practical question is whether to pursue the traditional two-vaccine approach or opt for a pentavalent vaccine. If a student has already completed their MenACWY series and just needs MenB, the standalone MenB vaccine remains appropriate. If a student needs both — say, a 16-year-old due for their MenACWY booster who has never received MenB — a pentavalent vaccine offers the appeal of fewer total injections and a streamlined schedule. Either path provides protection; the best choice depends on what the student has already received and how close they are to college enrollment.
The Neurological Stakes of Meningococcal Disease
For readers of a brain health and dementia care site, the consequences of meningococcal disease warrant particular attention. Bacterial meningitis directly attacks the meninges — the protective membranes surrounding the brain and spinal cord — and the resulting inflammation can cause lasting neurological damage. Among the one in five survivors who experience long-term effects, brain damage and seizures are among the most devastating outcomes. Hearing loss, which results from damage to the auditory nerve, is another common sequel that underscores how aggressively this infection targets the central nervous system. Research into post-meningitis cognitive outcomes has shown that survivors may experience difficulties with memory, executive function, and processing speed that persist well beyond the acute illness. These deficits can affect academic performance, career trajectory, and quality of life in ways that a 19-year-old and their family may not fully appreciate during the initial recovery.
While meningococcal meningitis is not a direct cause of dementia, the brain injury it produces shares some mechanistic features with other forms of acquired cognitive impairment — neuroinflammation, vascular damage, and neuronal loss. A warning worth stating plainly: meningococcal disease moves fast. A student can go from mild flu-like symptoms to sepsis and coma within 24 hours. Approximately 100 to 125 cases of meningococcal disease occur on college campuses each year, and 5 to 15 students die annually. U.S. meningococcal disease cases have increased sharply since 2021, now exceeding pre-pandemic levels. The speed and severity of the disease mean that vaccination is the primary defense — by the time symptoms are recognized, the window for preventing serious damage has often narrowed dramatically.
What Parents and Students Should Do Before Move-In Day
The most effective step is straightforward: request a copy of the student’s immunization records from their pediatrician and compare them against CDC recommendations, not just the college’s minimum requirements. A college may only require MenACWY, but that does not mean MenACWY alone is sufficient. If the records show no MenB vaccination, schedule it immediately — ideally at least six months before college entry so both doses can be completed before move-in.
A student who receives their first MenB dose in August and is not due for the second until February will have partial protection during the fall semester, which is better than none but not ideal. Students transferring between schools, taking gap years, or returning to campus housing after living off-campus should also reassess their vaccination status. The one-to-two-year protection window for MenB means a student who was vaccinated at 16 and is now 20 and moving back into a dorm may want to discuss the situation with their doctor, particularly if cases have been reported in their region.
Where Meningitis Vaccination Policy Is Heading
The approval and recommendation of pentavalent vaccines represent the most significant shift in meningococcal prevention strategy in years. If uptake of Penbraya and Penmenvy follows the pattern of other combination vaccines, MenB coverage could rise substantially without requiring new mandates or additional clinic visits. The broader age range of Penmenvy — approved down to age 10 — suggests that future ACIP guidance may push the combined vaccination earlier into adolescence, potentially integrating it into the same well-child visits where MenACWY is already given.
Public health officials are also watching the post-2021 rise in meningococcal disease rates closely. If the upward trend continues, the pressure for states to adopt MenB mandates for college entry will intensify. For now, the gap between what is recommended and what is required remains wide, and the responsibility falls largely on families and their healthcare providers to close it. The science on this one is not ambiguous — the vaccine exists, it works, and the students who need it most are the least likely to have received it.
Conclusion
The meningitis vaccine most college students are missing is the MenB vaccine. It covers serogroup B, which causes nearly two-thirds of meningococcal disease cases in the college-age population, yet fewer than one in five teens has completed the two-dose series. The MenACWY vaccine that most colleges require is important but insufficient on its own. Both are needed, and the newer pentavalent options — Penbraya and Penmenvy — can now deliver that combined protection in fewer shots.
Meningococcal disease is rare enough that many families have never encountered it, but severe enough that prevention should not be left to chance. A 10 to 15 percent fatality rate and a one-in-five chance of permanent neurological damage — including brain injury, hearing loss, and seizures — make this one of the highest-stakes vaccine decisions a family will face during the college preparation process. Check the immunization records, have the conversation with a doctor, and get the MenB vaccine scheduled before move-in day. The protection window is narrow, the timing matters, and the disease does not wait.
Frequently Asked Questions
Is the MenB vaccine required for college?
In most states, no. Only two states currently have specific MenB requirements for college entry. Twenty-six states mandate MenACWY, but the MenB vaccine falls under the CDC’s “shared clinical decision” category, meaning it is recommended but not universally required. Students should get it regardless of whether their school mandates it.
Can my student get the MenACWY and MenB vaccines at the same visit?
Yes, they can be administered at the same visit as separate shots. Alternatively, the newer pentavalent vaccines Penbraya and Penmenvy combine both into one injection, which may be preferable for students who need both.
How long does MenB vaccine protection last?
MenB protection is limited to approximately one to two years, which is why the CDC recommends vaccination at ages 16 to 18 — this timing ensures peak immunity during the first years of college when risk is highest. This is notably shorter than many other common vaccines.
My student was vaccinated against meningitis at age 11. Are they still protected at 18?
That dose was almost certainly MenACWY, and a booster at age 16 is recommended. If they received the booster, they have current MenACWY protection. However, that childhood vaccination did not include MenB, which requires a separate vaccine or one of the newer pentavalent options.
What makes college students higher risk for meningococcal disease?
Residence halls concentrate the risk factors: close physical proximity, shared personal items, irregular sleep patterns, and active social lives that involve close contact. Approximately 100 to 125 cases occur on college campuses annually, with 5 to 15 deaths each year.
Are there side effects from the MenB vaccine?
The most common side effects are soreness at the injection site, fatigue, headache, and muscle pain. These are generally mild and resolve within a day or two. Serious adverse reactions are rare. The risks of the vaccine are far smaller than the risks of meningococcal disease itself.
